STRO Sutro Biopharma: Projected Price to Earnings

Sutro Biopharma, Inc. (STRO) attracts leading oncobiologists by offering them participation in medical breakthroughs. The projected P/E ratio for Sutro Biopharma, Inc. (STRO) reflects the business valuation trend, with the current metric standing at 0.00. The company achieves cost optimization through contract manufacturing and research outsourcing. Its development strategy is based on cell-free protein synthesis and partnerships with industry behemoths to minimize risks.

sutrobio.com - STRO Future Price to Earnings Multiple (period 07/04/2022 - 11/12/2026)

Metric breakdowns and analytics for Sutro Biopharma, Inc (STRO)

- stock quotes and analyst forecast:

Stock Price Sutro Biopharma|STRO - Analyst Target Range

- company stock capitalization data:

Market Valuation Sutro Biopharma Inc.|STRO - Total Enterprise Value

- issuer book value statistics:

Accounting Value per Share Sutro Biopharma|STRO - Accounting Value of Company|Market Capitalization to Book Value Ratio sutrobio.com|STRO - Company Total Asset Base

- debt level and financial liquidity data:

- financial results and valuation multiples details:

STRO - Company Net Income|Future Profit Sutro Biopharma, Inc.|STRO - Market Cap to Net Income Ratio|Projected Price to Earnings Sutro Bio|STRO - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Sutro Biopharma Inc.|STRO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Sutro Biopharma|STRO - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months sutrobio.com|STRO - Earnings per share increase in current year|Earnings growth forecast for next year Sutro Biopharma, Inc.

Fundamental company analysis:Sutro Biopharma STRO

Signature product of Sutro Biopharma, Inc.

To identify fundamental stability, an investor analyzes the ratio of current market capitalization to projected annual earnings, which reflects market expectations regarding business efficiency. The forward P/E dynamics of Sutro Biopharma, Inc. (STRO) visualize the speed at which the valuation of Sutro Biopharma, Inc. (STRO) adapts to external shocks, linking the stability of licensing revenues from the conjugate platform with the future growth potential of the oncology drug portfolio.

Analysis of competing companies